marketcap
Facebook
Twitter
Telegram
Report an ErrorAnnual report 2022
added 04-28-2023
Jounce Therapeutics Financial Ratios 2011-2024 | JNCE
Annual Financial Ratios Jounce Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.9 | -4.6 | -8.8 | 3.7 | -4.7 | -47.0 | -37.4 | - | - | - | - | - |
P/S |
0.6 | 15.5 | 6.2 | 1.4 | 2.0 | 10.8 | 13.8 | - | - | - | - | - |
EPS |
-1.0 | -1.8 | -1.2 | 1.7 | -0.8 | -0.6 | -11 | -23.1 | - | - | - | - |
EV (Enterprise Value) |
-73.6 M | 350 M | 271 M | 187 M | 192 M | 879 M | 667 M | 8.12 M | 8.05 M | - | - | - |
EBITDA per Share |
-0.97 | -1.77 | -1.22 | 1.71 | -0.843 | -0.492 | -0.415 | - | - | - | - | - |
EV/EBITDA |
-3.8 | -5.8 | 2.7 | -3.0 | -50.7 | -37.4 | - | - | - | - | - | |
PEG |
0.01 | 0.07 | 0.05 | -0.01 | -0.1 | 1.83 | 0.7 | - | - | - | - | - |
P/B |
0.3 | 1.9 | 1.8 | 1.2 | 1.2 | 4.6 | 7.1 | - | - | - | - | - |
P/CF |
-1.6 | -5.0 | -13.8 | -6.7 | -2.0 | -7.3 | 2.9 | - | - | - | - | - |
ROE % |
-27.81 | -40.60 | -20.75 | 32.55 | -26.29 | -9.84 | -19.07 | - | - | - | - | - |
ROA % |
-23.96 | -35.96 | -17.95 | 27.60 | -12.77 | -5.54 | -5.05 | - | - | - | - | - |
ROCE % |
-28.53 | -40.69 | -20.06 | 27.58 | -21.02 | -8.21 | -8.01 | - | - | - | - | - |
Current Ratio |
7.2 | 8.7 | 10.9 | 12.1 | 2.9 | 4.1 | 1.7 | - | - | - | - | - |
DSO |
- | - | - | - | 2.3 | 90.2 | 7.0 | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Jounce Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | -0.6 | - | -0.72 | - | -0.59 | -0.08 | -0.58 | - | -0.73 | -0.82 | -0.78 | - | 2.99 | -0.21 | -0.38 | - | -0.23 | -0.14 | -0.4 | -0.29 | -0.13 | -0.11 | -0.02 | 0.11 | 0.06 | -7.23 | -6.81 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | -0.58 | - | -0.71 | - | -0.55 | -0.08 | -0.56 | - | -0.66 | -0.78 | -0.77 | - | 3.04 | -0.18 | -0.38 | - | -0.18 | -0.11 | -0.4 | -0.36 | -0.03 | -0.01 | 0.03 | 2.06 | 2.45 | -5.75 | -5.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-64.98 | -76.96 | -64.97 | -45.16 | -22.91 | -34.69 | -34.51 | -46.30 | -37.54 | 19.09 | 87.49 | 96.73 | 45.53 | 38.19 | -25.76 | -26.25 | -24.33 | -29.94 | -25.05 | -22.58 | -9.84 | -12.15 | -15.59 | 4.30 | 19.83 | 27.75 | 33.64 | 15.76 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-54.42 | -65.15 | -38.87 | -40.18 | -20.74 | -30.93 | -30.40 | -40.54 | -32.47 | 15.54 | 73.76 | 81.81 | 38.61 | 35.05 | -16.53 | -15.31 | -11.82 | -14.97 | -12.79 | -11.75 | -5.54 | -0.37 | 2.50 | -0.91 | -5.05 | -7.07 | -8.57 | -4.01 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-63.93 | -75.92 | -43.81 | -45.26 | -22.96 | -34.84 | -34.73 | -46.64 | -38.12 | 17.93 | 85.85 | 94.63 | 43.73 | 35.34 | -29.10 | -29.93 | -27.03 | -33.95 | -28.18 | -24.57 | -11.50 | -11.80 | -14.69 | 5.01 | 20.94 | 28.15 | 33.67 | 15.78 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
- | 5.5 | - | 8.3 | 8.8 | 9.7 | 11.1 | 11.9 | 7.4 | 7.4 | 7.4 | 7.4 | 6.6 | 6.6 | 6.6 | 6.6 | 1.9 | 1.9 | 1.9 | 1.9 | 2.3 | 2.3 | 2.3 | 2.3 | 1.4 | 1.4 | 1.4 | 1.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency